請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59385完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳忠仁(Chung-Jen Chen) | |
| dc.contributor.author | Wei-Hsien Su | en |
| dc.contributor.author | 蘇韋先 | zh_TW |
| dc.date.accessioned | 2021-06-16T09:22:10Z | - |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-06-27 | |
| dc.identifier.citation | 一、中文書籍
•林正寶 (2012)。企業併購: 國際觀點。第二版。台北:新陸書局。 •謝劍平 (2013)。財務管理：新觀念與本土化。第六版。台北: 智勝。 二、中文技術及研究報告 •湯澡薰 (2009)。各國藥品支付制度及藥價政策分析及評估。行政院衛生署九十八年度委託研究計劃。計畫編號：DOH98-NH-1008。 •勤業眾信Deloitte (2016)。新藥研發模式白皮書2016。 •劉祖惠、巫文玲、陳怡蓁、許毓真、賴瓊雅 (2015)。製藥產業年鑑2015。財團法人生物技術開發中心。台北市:經濟部技術處 產業技術知識服務計畫 (ITIS)。 三、英文期刊與雜誌 •Andersson, U., Johanson, J. and Vahlne, J. E. (1997). Organic Acquisitions in the Internationalization Process of the Business Firm. Management International Review, Special Issue (2), 67-84 •Ansoff, H. Igor. (1957). Strategies for diversification. Harvard Business Review, 35 (5), 113-124 •Chatterjee, S. (1986). Types of synergy and economic value: The impact of acquisitions on merging and rival firms. Strategic Management Journal, 7(2), 119-139. doi: 10.1002/smj.4250070203 •Drucker, P. F. (1981). Five Rules for Successful Acquisition. The Wall Street Journal, Oct 15, 28 •Halpern, Paul (1983). Corporate Acquisitions: A Theory of Special Cases? A Review of Event Studies Applied to Acquisitions. Journal of Finance, 38 (2), 297-317 •Hennart, J.F. & Park,Y.R. (1993). Greenfield vs. Acquisition The Strategy of Japanese Investors in the United States. Management Science, 39, 1054-1070 •Kitching, John (1967). Why Do Mergers Miscarry? Harvard Business Review, 45, 84-101 •Lewellen, W. G. (1971). A Pure Financial Rationale for the Conglomerate Merger. Journal of Finance, 26, 521-537 •Marcus, A. J. (1982). Risk Sharing and the Theory of the Firm. Bell Journal of Economics, 13, 369-378 •Mueller, D. C. (1969), A Theory of Conglomerate Mergers. Quarterly Journal of Economics, 83, 643-659 •Paine, F. T. and Power, D. J. (1984). Merger Strategy: an Examination of Drucker’s Five Rules for Successful Acquisition. Journal of Business Strategy, 5 (2), 99-110 •Prahalad, C.K. and Hamel, Gary (1990). The Core Competence of the Corporation. Harvard Business Review, 68 (3), 79–91 •Tetenbaum, T.J. (1999). Beating the Odds of Merger & Acquisition Failure: Seven Key Practices That Improve the Chance for Expected Integration and Synergies. Organizational Dynamics, 28 (2), 22-35 •Williamson O. E. (1976).Markets and Hierarchies: Analysis and Antitrust Implications. The Economic Journal, 86 (343), 619-621. doi: 10.2307/2230812 四、英文書籍 •Chandler, A.D. (1962). Strategy and structure: Chapters in the history of the American industrial enterprise. Massachusetts: MIT Press •Dorothy, Leonard-Barton (1995). Wellsprings of Knowledge: Building and Sustaining the Sources of Innovation. Boston: Harvard Business School Press •Glueck, W. F.(1976). Business policy: Strategy formation and management action. New York: McGraw-Hill •Grant, Robert M. (2010). Contemporary Strategy Analysis. 7th Edition. U.K.: John Wiley & Sons Ltd •Hill, Charles W. L. and Jones, Gareth R. (2008) Strategic Management Theory: An Integrated Approach. 9th Edition. Mason: South-Western Cengage Learning •Hymer, S. H. (1960). The International Operations of National Firms: A Study of Direct Foreign Investment. Ph.D. Dissertation. Published posthumously (1976). Cambridge: The MIT Press •Porter, Michael E. (1980). Competitive strategy: techniques for analyzing industries and competitors. Originally published in New York: Free Press 五、英文技術及研究報告 •Alcon Financial Report 2008-2016 •Allergan Financial Report 2008-2016 •BCC Research (2010 Apr). Ophthalmic Therapeutic Drugs: Technologies and Global Markets •Bloomberg (2014 May). Bloomberg M&A Data: Value of acquisitions made by top pharmaceutical companies between 1994 and 2014 •Contract Pharma (2008). Top 20 Pharmaceutical Companies Report •Contract Pharma (2010). Top 20 Pharmaceutical Companies Report •Evaluate Pharma (2016 Sep). Word Preview 2016, Outlook to 2022 •FirstWord (2014 May). FirstWord Lists – The 20 largest pharma M&A deals •Global Data research (2011). Top 25 pharma companies by global sales •IMS Health (2016). Pharmaceutical market: Worldwide revenue 2001-2015 •Jardines,Benjamin (2010). Big Pharma’s 2009-2013 Patent Cliff. Honors Capstonein Business •Ken Research (2016 Aug). Global Ophthalmology Drugs Market to 2022 -Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period •KPMG (2016 Jan). Deal Capsule: Transactions in Chemicals & Pharmaceuticals •Novartis Financial Report 2008-2016 •Occam’s Business Research & Consulting (2016). Global Ophthalmology Drug & Devices Market insights, Opportunities, Analysis, Market Shares and Forecast 2016–2022 •Pfizer Financial Report 2008-2016 •Santen Financial Report 2008-2016 •World Health Organization (WHO) (2010). Global Data on Visual Impairments 六、英文學位論文 •Hunt M.S. (1972). Competition in the major home appliance industry 1960-1970 Unpublished Ph.D. Dissertation. Harvard University | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59385 | - |
| dc.description.abstract | 跨國藥品廠商，透過購併策略以達到成長，已經成為趨勢。根據安侯建業聯合會計師事務所(KPMG)報告，2006年至2015年，十年間全球藥品廠商的購併案總金額就達到美金1兆2,920億，而總購併案數更是達到6,902件。
藥品產業是高知識密集與高附加價值的產業。根據寰宇藥品資料管理的資料顯示，自2008到2015年的年複合成長率為4.3%，可見全球藥品市場雖然規模龐大，但是整體成長已趨於穩定。跨國藥品廠商由於主要產品過專利期導致營收損失，且內部研發報酬率低，購併成為跨國藥品廠商持續追求成長的方式。 本論文的研究方法採取個案研究方式，選擇藥品產業個案公司之購併案進行分析。以五力分析架構分析藥品產業，並找出關鍵成功因素。針對個案相關歷史資料，透過次級資料分析和比較，探討個案公司之購併歷程、購併後的綜效與問題、以及結果。研究結果發現：本個案之購併在財務面具顯著規模變大與短期財務綜效；產品線雖有擴大，但互補性不強；在核心能耐的資源與能力方面，對客戶經營廣度與深度有幫助，強化眼科通路，但與買家的議價能力並未因此而提升。 跨國藥品廠商購併決策前，需要重新審視自身的優劣勢、資源、成長潛力，找出專注發展的領域，極大化資源投資報酬率。並且需要評估購併是否具互補性，能補足自身欠缺之資源與能力，如通路資源、研發能力、及行銷能力，產生整合效益的極大化，對企業長期成長的幫助性更大。考慮購併策略的整體風險是很重要的，當採行多角化進入其他市場，需要同時考量標的市場之規模與成長。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2021-06-16T09:22:10Z (GMT). No. of bitstreams: 1 ntu-106-P04E41018-1.pdf: 1532737 bytes, checksum: 40342fee9f83dcfcf7c0c1dc2c33bfe2 (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 口試委員會審定書……………………………………………i
誌謝………………………………………………ii 中文摘要………………………………………………iii 英文摘要………………………………………………iv 目錄………………………………………………v 圖目錄…………………………………………………vii 表目錄……………………………………………………ix 第一章 緒論………………………………………1 第一節 研究背景與動機…………………1 第二節 研究目的……………………………2 第三節、研究方法與架構…………………2 第二章 文獻探討…………………………………4 第一節 五力分析………………………4 第二節 策略群組………………8 第三節 核心能耐…………………………………9 第四節 成長策略理論………………………12 第五節 購併相關理論………………………14 第三章 藥品產業分析………………………………21 第一節 產業發展趨勢分析……………………21 第二節 產業結構與關鍵成功因素分析………29 第三節 產業競爭者分析…………………………33 第四節 產業整併變化趨勢………………………………37 第四章 購併個案研究……………………………………42 第一節 個案公司介紹……………………………………42 第二節 購併歷程…………………………………………47 第三節 購併後之綜效與問題……………………………49 第四節 購併策略分析…………………………………56 第五章 結論與建議……………………………………………59 第一節 研究結論…………………………………………59 第二節 研究建議……………………………………………60 第三節 研究限制……………………………………………63 參考文獻……………………………………………………64 | |
| dc.language.iso | zh-TW | |
| dc.subject | 核心能耐 | zh_TW |
| dc.subject | 藥品產業 | zh_TW |
| dc.subject | 購併 | zh_TW |
| dc.subject | 關鍵成功因素 | zh_TW |
| dc.subject | 綜效 | zh_TW |
| dc.subject | core competence | en |
| dc.subject | Pharmaceutical industry | en |
| dc.subject | mergers and acquisitions (M&A) | en |
| dc.subject | key successful factors (KSFs) | en |
| dc.subject | synergy | en |
| dc.title | 跨國藥品廠商購併策略分析 – 以諾華購併愛爾康為例 | zh_TW |
| dc.title | The M&A Strategy Analysis of Multi-national Pharmaceutical Company – A Case Study of Novartis and Alcon | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 郭佳瑋,陳俊忠 | |
| dc.subject.keyword | 藥品產業,購併,關鍵成功因素,綜效,核心能耐, | zh_TW |
| dc.subject.keyword | Pharmaceutical industry,mergers and acquisitions (M&A),key successful factors (KSFs),synergy,core competence, | en |
| dc.relation.page | 67 | |
| dc.identifier.doi | 10.6342/NTU201701091 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2017-06-27 | |
| dc.contributor.author-college | 進修推廣部 | zh_TW |
| dc.contributor.author-dept | 事業經營碩士在職學位學程 | zh_TW |
| 顯示於系所單位： | 事業經營碩士在職學位學程 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf 未授權公開取用 | 1.5 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。